Long Xiaodib in DLBCL

The remaining question for this regimen is besides this probably limited activity in truly refractory patient is how long should we continue the drug. We have a few patients that are NCR for more than one year. There are no clear answer regarding the exposure of lymphoma to both taphacetamab and loncastiximab, which both targets CD19 on the surface of B cell as well as CAR-T. The data appear to be reassuring, but you may want to preserve an interval between the infusion of CAR-T and the lot administration of this drug.